Comparability of “Enoxamed” a Tunisian Generic Enoxaparin with the Originator Product: Non-clinical and Clinical Studies

Sassi, Mouna; Beltaief, Kaouther

doi:10.4172/jbb.1000304

Cited by 1 publication

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Generally, LMWHs differ in their PK and PD properties, which could be possibly due to the depolymerization processes or the manufacturing methods that result in its structural variability 12 . Therefore, producing biosimilar LMWH is a challenging task and its market authorization requires adequate evidence that it meets the same standards of quality, efficacy, and safety as of its innovator 13 . To determine bioequivalence, we conducted this study to compare the biological activity of “Cloti‐Xa™”, an enoxaparin sodium‐prefilled syringe of 40 mg/0.4 ml (4000 IU/0.4 ml) with that of the innovator product “Clexane ® ”.…”

Section: Discussionmentioning

confidence: 99%

Bioequivalence of a biosimilar enoxaparin (Cloti‐Xa™) and its innovator (Clexane^®): A single‐dose, randomized, double‐blind, two‐period, two‐treatment, two‐sequence, crossover, balanced study in healthy human subjects

Saxena

Chaudhary

et al. 2022

Pharmacology Res & Perspec

View full text Add to dashboard Cite

Currently, several biosimilars of low‐molecular‐weight heparins (LMWHs) with differing potencies are being developed and marketed globally. Thus, it is important that the potency of each biosimilar LMWH be compared with its innovator's molecule. The present study aimed to determine the bioequivalence of biosimilar (Cloti‐Xa™) and innovator (Clexane ® ) formulations of enoxaparin sodium (40 mg/0.4 ml) in healthy human volunteers. It was conducted as a single‐dose, randomized, double‐blind, two‐period, two‐treatment, two‐sequence, crossover, balanced, pharmacodynamic study (NCT05265676). The participants were sequentially and randomly administered subcutaneous injections of Cloti‐Xa™ (test) and Clexane ® (reference), separated by a one‐week washout period. To assess the Anti‐Xa & Anti‐IIa activities, tissue factor pathway inhibitor (TFPI) release and activated partial thromboplastin time (aPTT), blood samples were obtained at various timepoints upto 24 h after the drug administration. Bioequivalence was concluded if the two‐sided 90% CI for the test to reference ratio of the population is within 80%–125% for each of the Ln‐transformed values of A max and AUEC t for Anti‐Xa and Anti‐IIa. TFPI and aPTT data were submitted as supportive evidence. The study sample consisted of twenty‐four male participants. The 90% CIs of A max and AUEC t for Anti‐Xa activity were 105.50%–113.90% and 103.97%–112.08%, and for Anti‐IIa activity were 106.56%–117.90% and 107.35%–124.86%, respectively. In addition, the 90% CI of the ratio of Anti‐Xa/Anti‐IIa activity falls within the acceptance criteria. TFPI and aPTT profiles were similar for both products. No serious adverse events were observed during the study. Conclusively, the results showed that Cloti‐Xa™ and Clexane ® are bioequivalent and well‐tolerated.

show abstract

Section: Discussionmentioning

confidence: 99%

Bioequivalence of a biosimilar enoxaparin (Cloti‐Xa™) and its innovator (Clexane^®): A single‐dose, randomized, double‐blind, two‐period, two‐treatment, two‐sequence, crossover, balanced study in healthy human subjects

Saxena

Chaudhary

et al. 2022

Pharmacology Res & Perspec

View full text Add to dashboard Cite

show abstract

Comparability of “Enoxamed” a Tunisian Generic Enoxaparin with the Originator Product: Non-clinical and Clinical Studies

Cited by 1 publication

References 13 publications

Bioequivalence of a biosimilar enoxaparin (Cloti‐Xa™) and its innovator (Clexane^®): A single‐dose, randomized, double‐blind, two‐period, two‐treatment, two‐sequence, crossover, balanced study in healthy human subjects

Bioequivalence of a biosimilar enoxaparin (Cloti‐Xa™) and its innovator (Clexane^®): A single‐dose, randomized, double‐blind, two‐period, two‐treatment, two‐sequence, crossover, balanced study in healthy human subjects

Contact Info

Product

Resources

About

Comparability of “Enoxamed” a Tunisian Generic Enoxaparin with the Originator Product: Non-clinical and Clinical Studies

Cited by 1 publication

References 13 publications

Bioequivalence of a biosimilar enoxaparin (Cloti‐Xa™) and its innovator (Clexane®): A single‐dose, randomized, double‐blind, two‐period, two‐treatment, two‐sequence, crossover, balanced study in healthy human subjects

Bioequivalence of a biosimilar enoxaparin (Cloti‐Xa™) and its innovator (Clexane®): A single‐dose, randomized, double‐blind, two‐period, two‐treatment, two‐sequence, crossover, balanced study in healthy human subjects

Contact Info

Product

Resources

About

Bioequivalence of a biosimilar enoxaparin (Cloti‐Xa™) and its innovator (Clexane^®): A single‐dose, randomized, double‐blind, two‐period, two‐treatment, two‐sequence, crossover, balanced study in healthy human subjects

Bioequivalence of a biosimilar enoxaparin (Cloti‐Xa™) and its innovator (Clexane^®): A single‐dose, randomized, double‐blind, two‐period, two‐treatment, two‐sequence, crossover, balanced study in healthy human subjects